Roche Data Highly Anticipated at American Society of Clinical Oncology; Rumored to Present Positive Progress in Skin, Lung, and Ovarian Cancer Drugs
Roche Holding AG (ROG.VX) will present data on four key cancer drugs, including Avastin in ovarian cancer, at this year's American Society of Clinical Oncology meeting, the Swiss drugmaker said on Wednesday. Roche is hoping the data will remind markets that it still boasts one of the strongest pipelines in the industry and remains a leader in cancer. The Basel-based group is trying to get back on track after hitting a number of product setbacks last year, while demand for Avastin has weakened after U.S. authorities proposed revoking its approval in breast cancer.